PTH and nephrolithiasis: Awareness must be increased among clinicians that in the event of hypercalcemia with low PTH concentrations and in patients with nephrolithiasis and/or nephrocalcinosis, pathogenic CYP24A1 mutations should be considered as a potential underlying disease.